aTYR PHARMA annual operating margin
2019
2020
2022
2023
2024
2025
aTYR PHARMA Operating Margin Growth & History (ATYR)
aTYR PHARMA's operating margin was −40,856.32% for fiscal 2025.
View full aTYR PHARMA company overviewaTYR PHARMA annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −40,856.32% | −11956.74 pp |
| 2024 | 2024-12-31 | −28,899.57% | −13341.78 pp |
| 2023 | 2023-12-31 | −15,557.79% | −15111.00 pp |
| 2022 | 2022-12-31 | −446.79% | — |
| 2020 | 2020-12-31 | −152.19% | +5292.84 pp |
| 2019 | 2019-12-31 | −5,445.02% | — |
aTYR PHARMA quarterly operating margin
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q3.23
Q1.24
Q3.25
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −14,076.32% | — |
| Q1 2024 | 2024-03-31 | −7,079.15% | — |
| Q3 2023 | 2023-09-30 | −3,573.65% | — |
| Q4 2020 | 2020-12-31 | −240.62% | — |
| Q3 2020 | 2020-09-30 | −4,400.00% | −1411.96 pp |
| Q2 2020 | 2020-06-30 | −3,342.86% | +2658.21 pp |
| Q1 2020 | 2020-03-31 | 23.05% | — |
| Q3 2019 | 2019-09-30 | −2,988.04% | — |
| Q2 2019 | 2019-06-30 | −6,001.06% | — |
aTYR PHARMA operating margin trends
Over the last five fiscal years, aTYR PHARMA's operating margin decreased from −152.19% to −40,856.32%, a change of −40704.13 percentage points. The latest reported quarter, Q3 2025, shows −14,076.32%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review aTYR PHARMA source filings ↗Community posts
aTyr outlines a new Phase 3 sarcoidosis study after FDA discussions
aTyr Pharma ($ATYR) said it had aligned with the FDA on the design of a Phase 3 study of efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The planned trial would enroll 372 patients and compare treatment with pla ...
